Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Turning Question Marks Into Check Marks: HHS Blueprint One Year Later

Executive Summary

Direct-to-consumer ad rule is first of a series of high-profile regulations aimed at lowering drug prices and reducing out-of-pocket costs that the Trump Administration hopes to implement by 2020.

You may also be interested in...



US Affordable Care Act Impact On Cancer Care Quantified At ASCO

A series of abstracts highlight the impact of the ACA and Medicaid expansion on ovarian cancer diagnosis, racial disparities in time to treatment and the impact of insurance type on myeloma survival.

DTC Ad Final Rule Means Reliance On PhRMA Program Risks Enforcement Action – Azar

Nevertheless, the Pharmaceutical Research and Manufacturers of America announces enhancement of its drug pricing disclosures voluntary program, a Medicines Assistance Tool website that links to individual company sites, in response to the US rule.

Trump Drug Pricing Plan Includes Part D Surprises, Challenges PBM Business Model

The reform 'blueprint' might actually live up to its hype.

Topics

UsernamePublicRestriction

Register

PS125265

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel